Cerevel Therapeutics Holdings Overview

Cerevel Therapeutics Holdings Selling, General & Admin

Selling, General & Admin expenses for CERE.

Quarterly SG&A Expenses

$36.23M

↑ 69.54% YoY

As of Mar 31, 2024

Annual SG&A Expenses (TTM)

$125.98M

↑ 37.76% YoY

Trailing 12 months ending Mar 31, 2024

Average SG&A Expenses (Comparison Companies)

Selling, General & Admin History

Selling, General & Admin Comparison

Annual Selling, General & Admin Growth Rate (%)

Annual Selling, General & Admin Growth (Absolute)

Jump to metric

Total Revenue Cost of Revenue Gross Profit Research & Development Selling, General & Admin Operating Income Other Income Expense Net EBIT Income Tax Net Income Profit Margin